KRAS and neoplasm: Among 87 patients of the study population, none of 21 patients with tumours presenting whatever mutation responded to the treatment, in comparison with 22 (37%) of 60 patients with KRAS 61 and 146 and BRAF wild-type disease (P=0.0005; Table 5).